Evogene Ltd. - Ordinary Shares (EVGN) News
Filter EVGN News Items
EVGN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
EVGN News Highlights
- For EVGN, its 30 day story count is now at 3.
- Over the past 6 days, the trend for EVGN's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about EVGN are AG and DRUG.
Latest EVGN News From Around the Web
Below are the latest news stories about EVOGENE LTD that investors may wish to consider to help them evaluate EVGN as an investment opportunity.
Biomica CEO to Participate in Panel Discussion at 7th European Annual Microbiome MovementBiomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced its CEO and VP R&D will both be participating in 7th Annual Microbiome Movement Drug Development Europe, taking place in London, UK, between January 31 and February 2, 2023. |
Casterra Announces Agreement with World Leading Energy Company to Cultivate its Castor Varieties at Commercial ScaleCasterra Ag Ltd. ("Casterra"), the integrated castor cultivation solution company and a subsidiary of Evogene Ltd. ("Evogene") (Nasdaq: EVGN) (TASE: EVGN), announced today that it has entered into an agreement with one of the world's leading energy companies, whereby Casterra will provide its unique castor varieties and its broad know-how in cultivation of castor at a commercial scale for biofuel production. |
All You Need to Know About Evogene (EVGN) Rating Upgrade to Strong BuyEvogene (EVGN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy). |
Biomica CEO to Attend the JP Morgan Healthcare Week in San Francisco between January 9-11, 2023Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), today announced it will be in attendance at the Healthcare Week taking place together with the J.P. Morgan Healthcare Conference in San Francisco. The conference is one of the industry's largest conferences of the year. |
Evogene Ltd. (NASDAQ:EVGN) Q3 2022 Earnings Call TranscriptEvogene Ltd. (NASDAQ:EVGN) Q3 2022 Earnings Call Transcript November 17, 2022 Evogene Ltd. beats earnings expectations. Reported EPS is $-0.16, expectations were $-0.2. Operator: Ladies and gentlemen, thank you for standing by. Welcome to Evogene’s Third Quarter 2022 Results Conference Call. All participants are at present in listen-only mode. Following management’s formal presentation, instructions will […] |
Biomica Raises $20 Million in a Financing Round to Advance its Pipeline of Microbiome-based TherapeuticsBiomica Ltd., a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), today announced the signing of a definitive agreement for a $20 million financing round, to be led by Shanghai Healthcare Capital (SHC). The financing is subject to customary closing conditions, including clearance by Chinese regulatory authorities. |
Evogene to Receive $3.5 million Payment Related to Patent Portfolio under its Existing Seed Traits Collaboration with BayerEvogene Ltd. (Nasdaq: EVGN) (TASE: EVGN) (the "Company", "Evogene"), a leading computational biology company targeting to revolutionize life-science product discovery and development across multiple market segments, announced today that Bayer will pay Evogene an amount of $3.5 million under their joint seed traits collaboration agreement. |
Evogene (EVGN) Reports Q3 Loss, Tops Revenue EstimatesEvogene (EVGN) delivered earnings and revenue surprises of 20% and 79.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock? |
Evogene Reports Third Quarter 2022 Financial ResultsEvogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company targeting to revolutionize life-science based product discovery and development utilizing cutting edge computational biology technologies, across multiple market segments, announced today its financial results for the third quarter, ended September 30, 2022. |
Casterra Signs Royalty Agreement with Titan for Castor Oil Sales in South-Eastern AfricaCasterra Ag Ltd. ("Casterra"), the castor seeds technology developer whose mission is to provide the most advanced castor bean seed varieties and comprehensive ag-service solutions to castor cultivators and manufacturers, and a subsidiary of Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) ("Evogene"), announced today that it signed a long-term royalty agreement with Titan Castor Farms Limited ("Titan"), a Zambian cultivator, manufacturer and distributor of castor oil. |